[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/15/2018 – 10/19/2018:

1) VBLT – Vascular Biogenics Ltd. – Trading Below Cash
a. Buy at < ~ $1.38
b. Sell at >~ $3.00
c. Catalysts:
1. Phase 3 – A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL); 20221201; 20230630; https://ClinicalTrials.gov/show/NCT03398655

2) ADXS – Advaxis, Inc.
a. Buy at < ~ $0.64
b. Sell at >~ $1.15
c. Catalysts:
1. Phase 1Phase 2 – ADXS11-001 High Dose HPV+ Cervical Cancer; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02164461
2. Phase 2 – A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy; 20190301; 20190331; https://ClinicalTrials.gov/show/NCT02531854
3. Phase 2 – Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer; 20181002; 20181031; https://ClinicalTrials.gov/show/NCT01266460
4. Phase 1Phase 2 – Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors; 20180801; 20181231; https://ClinicalTrials.gov/show/NCT02386501
5. Phase 2 – ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer; 20180801; 20190831; https://ClinicalTrials.gov/show/NCT02002182
6. Phase 2 – Phase 2 Study of ADXS11-001 in Subjects With Carcinoma of the Anorectal Canal; 20200301; 20220331; https://ClinicalTrials.gov/show/NCT02399813
7. Phase 3 – Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer; 20200601; 20210630; https://ClinicalTrials.gov/show/NCT02853604
8. Phase 1 – Expressing Personalized Tumor Antigens Study; 20190901; 20200930; https://ClinicalTrials.gov/show/NCT03265080
9. Phase 1Phase 2 – ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer – KEYNOTE-046; 20190401; 20191231; https://ClinicalTrials.gov/show/NCT02325557
10. Phase 1Phase 2 – Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer; 20190701; 20191231; https://ClinicalTrials.gov/show/NCT02291055

3) CFMS – Conformis, Inc.
a. Buy at < ~ $0.88
b. Sell at >~ $1.30

4) CYCC – Cyclacel Pharmaceuticals, Inc. – Trading Below Cash
a. Buy at < ~ $1.28
b. Sell at >~ $1.80
c. Catalysts:
1. Phase 1 trial presented at AACR April 15, 2018. Updated data due 2018. – CYC065 – Advanced cancers – Phase 1; 20181231; 20181231; http://investor.cyclacel.com/news-releases/news-release-details/cyclacel-pharmaceuticals-reports-first-quarter-2018-financial
2. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3
3. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11
4. Phase 1Phase 2 – Olaparib + Sapacitabine in BRCA Mutant Breast Cancer; 20200622; 20250622; https://ClinicalTrials.gov/show/NCT03641755
5. Phase 2 – Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23); 20190701; 20190731; https://ClinicalTrials.gov/show/NCT01253460

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks < ~ $10 to Buy next week, 10/15/2018 – 10/19/2018, and Why?

Disclaimer

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/08/2018 – 10/12/2018:

1) RXII – RXi Pharmaceuticals Corporation
a. Buy at < ~ $0.55
b. Sell at >~ $2.19

2) VBLT – Vascular Biogenics Ltd. – Trading Below Cash
a. Buy at < ~ $1.55
b. Sell at >~ $3.00
c. Catalysts:
1. VBL Therapeutics to Present at Upcoming Conferences in October; 20181003; 20181011; https://finance.yahoo.com/news/vbl-therapeutics-present-upcoming-conferences-120000385.html
2. Phase 3 – A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL); 20221201; 20230630; https://ClinicalTrials.gov/show/NCT03398655

3) CFMS – Conformis, Inc.
a. Buy at < ~ $0.88
b. Sell at >~ $1.30

4) VSAR – Versartis, Inc. – Trading Below Cash
a. Buy at < ~ $1.30
b. Sell at >~ $1.90
c. Catalysts:
1. Phase 3 – A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency; 20190930; 20200131; https://ClinicalTrials.gov/show/NCT03145831
2. Phase 2 – Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in AGHD; 20191201; 20191231; https://ClinicalTrials.gov/show/NCT02719990

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks < ~ $10 to Buy next week, 10/08/2018 – 10/12/2018, and Why?

Disclaimer

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/01/2018 – 10/05/2018:

1) RXII – RXi Pharmaceuticals Corporation
a. Buy at < ~ $1.12
b. Sell at >~ $2.19

2) VBLT – Vascular Biogenics Ltd. – Trading Below Cash
a. Buy at < ~ $1.55
b. Sell at >~ $3.00
c. Catalysts:
1. VBL Therapeutics to Present at Upcoming Conferences in October; 20181003; 20181011; https://finance.yahoo.com/news/vbl-therapeutics-present-upcoming-conferences-120000385.html
2. Phase 3 – A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL); 20221201; 20230630; https://ClinicalTrials.gov/show/NCT03398655

3) UAVS – AgEagle Aerial Systems, Inc.
a. Buy at < ~ $1.52
b. Sell at >~ $2.22

4) VSAR – Versartis, Inc. – Trading Below Cash
a. Buy at < ~ $1.30
b. Sell at >~ $1.90
c. Catalysts:
1. Phase 3 – A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency; 20190930; 20200131; https://ClinicalTrials.gov/show/NCT03145831
2. Phase 2 – Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in AGHD; 20191201; 20191231; https://ClinicalTrials.gov/show/NCT02719990

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks < ~ $10 to Buy next week, 10/01/2018 – 10/05/2018, and Why?

Disclaimer

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 08/06/2018 – 08/10/2018:

1) UAVS – AgEagle Aerial Systems, Inc.
a. Buy at < ~ $1.52
b. Sell at >~ $10.95

2) CBAK – CBAK Energy Technology, Inc.
a. Buy at < ~ $0.65
b. Sell at >~ $2.35

3) GNMX – Aevi Genomic Medicine, Inc.
a. Buy at < ~ $0.83
b. Sell at >~ $2.28
c. Catalysts:
1. Phase 2 – PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT03265119
2. – A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT03233867
3. Phase 1 – Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohns Disease; 20181001; 20181130; https://ClinicalTrials.gov/show/NCT03169894

4) LIFE – aTyr Pharma, Inc. – Trading Below Cash
a. Buy at < ~ $0.70
b. Sell at >~ $1.32
c. Catalysts:
1. Phase 1Phase 2 – Safety, Tolerability, PK, and Activity of ATYR1940 in Patients With Muscular Dystrophy – Study Extension; 20180501; 20180831; https://ClinicalTrials.gov/show/NCT02531217

5) IGLD – Internet Gold – Golden Lines Ltd. – Trading Below Cash
a. Buy at < ~ $2.40
b. Sell at >~ $4.05

6) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.95
b. Sell at >~ $1.53

7) SUNW – Sunworks, Inc.
a. Buy at < ~ $0.90
b. Sell at >~ $1.30

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 08/06/2018 – 08/10/2018, and Why?

Disclaimer

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 07/30/2018 – 08/03/2018:

1) UAVS – AgEagle Aerial Systems, Inc.
a. Buy at < ~ $1.52
b. Sell at >~ $10.95

2) CBAK – CBAK Energy Technology, Inc.
a. Buy at < ~ $0.85
b. Sell at >~ $2.35

3) GNMX – Aevi Genomic Medicine, Inc.
a. Buy at < ~ $0.83
b. Sell at >~ $2.28
c. Catalysts:
1. Phase 2 – PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT03265119
2. – A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT03233867
3. Phase 1 – Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohns Disease; 20181001; 20181130; https://ClinicalTrials.gov/show/NCT03169894

4) LIFE – aTyr Pharma, Inc. – Trading Below Cash
a. Buy at < ~ $0.79
b. Sell at >~ $1.32
c. Catalysts:
1. Phase 1Phase 2 – Safety, Tolerability, PK, and Activity of ATYR1940 in Patients With Muscular Dystrophy – Study Extension; 20180501; 20180831; https://ClinicalTrials.gov/show/NCT02531217

5) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.95
b. Sell at >~ $1.53

6) SUNW – Sunworks, Inc.
a. Buy at < ~ $0.90
b. Sell at >~ $1.30

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 07/30/2018 – 08/03/2018, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 07/13/2018 include:

1. $CHFS – CHF Solutions, Inc. :
   1. Book/sh = $3.07
2. $CLDX – Celldex Therapeutics, Inc. :
   1. Book/sh = $0.95
3. $DCAR – DropCar, Inc. :
   1. Book/sh = $2.00
4. $JAGX – Jaguar Health, Inc. :
   1. Book/sh = $2.43
5. $KOOL – Cesca Therapeutics Inc. :
   1. Book/sh = $2.94
6. $OSN – Ossen Innovation Co., Ltd. :
   1. Book/sh = $15.50
7. $OVAS – OvaScience, Inc. :
   1. Book/sh = $1.60
8. $PRSS – CafePress Inc. :
   1. Book/sh = $1.93
9. $RTTR – Ritter Pharmaceuticals, Inc. :
   1. Book/sh = $2.71
10. $XGTI – xG Technology, Inc. :
    1. Book/sh = $0.99

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 07/13/2018 include:

1. $CHFS – CHF Solutions, Inc. :
   1. Cash/sh = $2.35
2. $CLDX – Celldex Therapeutics, Inc. :
   1. Cash/sh = $0.77
3. $EGLT – Egalet Corporation :
   1. Cash/sh = $1.41
4. $HMNY – Helios and Matheson Analytics Inc. :
   1. Cash/sh = $0.76
5. $OVAS – OvaScience, Inc. :
   1. Cash/sh = $1.64
6. $PRSS – CafePress Inc. :
   1. Cash/sh = $1.35
7. $RTTR – Ritter Pharmaceuticals, Inc. :
   1. Cash/sh = $3.49
8. $VXRT – Vaxart, Inc. :
   1. Cash/sh = $8.50

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

“What Makes A Great Investor?” => http://www.athrasher.com/what-makes-a-great-investor/

What do you think of these 7 Traits that Mark says that you need to be a Great Investor?

Let’s discuss them all, and anything else that you believe makes A Great Investor, herein, ok?

I hope this all helps and Have a Great Trading Day!

– Michael S. DeVries

[Michael DeVries]

“Does anyone really succeed at trading?” => https://adamhgrimes.com/does-anyone-really-succeed-at-trading/

What do you think about all of Adam’s advice in this posting?

Let’s discuss it all herein, ok?

I hope this all helps you to succeed at trading and to become a full time trader, if that is what you want / your goal!

– Michael S. DeVries

[Michael DeVries]

“10 Secrets to Achieve Financial Success: Critique, Key Takeaways, and Analysis for Cancer Investors” => http://www.investagainstcancer.com/secrets-to-financial-success-critique/

What do you all, Cancer/Biotechnology Investors, think about each of those “10 Secrets”?

Which of those “10 Secrets” do you use? and which have worked (Best) for you?

Let’s discuss them all herein, ok?

I hope this all helps. Good Luck! and Have a Great Trading Day!

– Michael S. DeVries

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 07/09/2018 – 07/13/2018:

1) UAVS – AgEagle Aerial Systems, Inc.
a. Buy at < ~ $1.52
b. Sell at >~ $10.95

2) RGSE – Real Gds Solar
a. Buy at < ~ $0.37
b. Sell at >~ $1.36

3) RXII – RXi Pharmaceuticals Corporation
a. Buy at < ~ $1.78
b. Sell at >~ $6.30

4) CBAK – CBAK Energy Technology, Inc.
a. Buy at < ~ $0.85
b. Sell at >~ $2.35

5) GNMX – Aevi Genomic Medicine, Inc.
a. Buy at < ~ $0.98
b. Sell at >~ $2.28
c. Catalysts:
1. Phase 2 – PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT03265119
2. – A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT03233867
3. Phase 1 – Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohns Disease; 20181001; 20181130; https://ClinicalTrials.gov/show/NCT03169894

6) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.95
b. Sell at >~ $1.53

7) CFMS – ConforMIS, Inc.
a. Buy at < ~ $1.15
b. Sell at >~ $1.82

8) IPWR – Ideal Power Inc.
a. Buy at < ~ $1.00
b. Sell at >~ $1.60

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 07/09/2018 – 07/13/2018, and Why?

[Michael DeVries]

“New Research Could Lead to DNA 3D Printer” => https://3dprint.com/217369/new-research-dna-3d-printer/

How long do you predict that it will be before we are able to quickly and reliable 3D Print DNA?

What do you predict will be all of the implications of being able to 3D Print DNA?

How will this change/disrupt our lives? other industries? the (world) economy?

Let’s discuss this all herein, ok?

I hope this all helps and Have a Great Future!

– Michael S. DeVries

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 06/25/2018 – 06/29/2018:

1) AGRX – Agile Therapeutics, Inc. – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $1.04

2) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.95
b. Sell at >~ $1.53

3) PRSS – CafePress Inc. – Trading Below Cash
a. Buy at < ~ $1.26
b. Sell at >~ $1.99

4) IPWR – Ideal Power Inc.
a. Buy at < ~ $1.06
b. Sell at >~ $1.60

5) CHFS – CHF Solutions, Inc.
a. Buy at < ~ $2.50
b. Sell at >~ $3.75
c. Catalysts:
1. Phase 3 – Study of Organ Perfusion With Custodiol-N Solution Compared With Custodiol Solution in Heart Transplantation; 20190201; 20190831; https://ClinicalTrials.gov/show/NCT02869022
2. Phase 3 – Digoxin Short Term Treatment Assessment Randomized Trial in AHF; 20181201; 20190630; https://ClinicalTrials.gov/show/NCT02544815
3. Phase 3 – Glutamate for Metabolic Intervention in Coronary Surgery II; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02592824
4. NA – Group Medical Visits in Heart Failure; 20190430; 20190630; https://ClinicalTrials.gov/show/NCT02481921
5. Phase 3 – Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure; 20190301; 20190630; https://ClinicalTrials.gov/show/NCT03458325
6. Phase 2 – Nebulized Inhaled Milrinone in a Hospitalized Advanced Heart Failure Population; 20190301; 20190301; https://ClinicalTrials.gov/show/NCT02077010
7. Phase 2 – A Dose Ranging Study of CHF 1531 in Asthmatic Subjects; 20180730; 20180730; https://ClinicalTrials.gov/show/NCT03086460
8. Phase 2 – Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction; 20180701; 20190731; https://ClinicalTrials.gov/show/NCT03074591
9. NA – SystemCHANGE™ Intervention on Medication Adherence in Older Adults With Heart Failure; 20180701; 20180731; https://ClinicalTrials.gov/show/NCT03162848
10. Phase 2 – A Study of CLR325 in Chronic Stable Heart Failure Patients.; 20180924; 20180924; https://ClinicalTrials.gov/show/NCT02696967
11. Phase 2 – Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients; 20180801; 20190831; https://ClinicalTrials.gov/show/NCT02362646
12. NA – Blood Volume and Hemodynamic Analysis in Patients With Chronic Heart Failure; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02120014
13. NA – Saline Versus Lactated Ringers Solution: The SOLAR Fluid Trial; 20200901; 20220930; https://ClinicalTrials.gov/show/NCT02565420
14. Phase 2 – Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in HFpEF (INABLE-Training); 20200401; 20201231; https://ClinicalTrials.gov/show/NCT02713126
15. NA – New Model of Care in Heart Failure; 20200228; 20201231; https://ClinicalTrials.gov/show/NCT03476590
16. Phase 3 – International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device; 20210801; 20210831; https://ClinicalTrials.gov/show/NCT02656329
17. Phase 3 – Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency; 20210101; 20220630; https://ClinicalTrials.gov/show/NCT03037931
18. Phase 1Phase 2 – Diffusion MRI in Heart Failure; 20201201; 20201231; https://ClinicalTrials.gov/show/NCT02973633
19. Phase 2 – Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs; 20191101; 20191130; https://ClinicalTrials.gov/show/NCT02941705
20. NA – Dietetics Education Focused on Malnutrition Prevention; 20190901; 20190930; https://ClinicalTrials.gov/show/NCT02892747
21. NA – Comprehensive Medication Monitoring on Heart Failure Patient Outcomes; 20190701; 20190930; https://ClinicalTrials.gov/show/NCT03519477
22. NA – Telehealth for Emergency-Community Continuity of Care Connectivity Via Home-Telemonitoring Randomized Controlled Trial; 20191231; 20200130; https://ClinicalTrials.gov/show/NCT03439384
23. Phase 4 – Albumin in Cardiac Surgery; 20191201; 20200331; https://ClinicalTrials.gov/show/NCT02560519
24. Phase 4 – Evaluating Iron Protein Succinylate Oral Solution in Treating Chronic Heart Failure and Iron Deficiency; 20191201; 20191231; https://ClinicalTrials.gov/show/NCT03344523

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 06/25/2018 – 06/29/2018, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 06/15/2018 include:

1. $CLDX – Celldex Therapeutics, Inc. :
   1. Book/sh = $0.95
2. $DCAR – DropCar, Inc. :
   1. Book/sh = $3.01
3. $KOOL – Cesca Therapeutics Inc. :
   1. Book/sh = $3.36
4. $OVAS – OvaScience, Inc. :
   1. Book/sh = $1.80
5. $XGTI – xG Technology, Inc. :
   1. Book/sh = $0.99

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 06/15/2018 include:

1. $CLDX – Celldex Therapeutics, Inc. :
   1. Cash/sh = $0.85
2. $EGLT – Egalet Corporation :
   1. Cash/sh = $1.41
3. $HMNY – Helios and Matheson Analytics Inc. :
   1. Cash/sh = $0.52
4. $OVAS – OvaScience, Inc. :
   1. Cash/sh = $1.88
5. $RTTR – Ritter Pharmaceuticals, Inc. :
   1. Cash/sh = $4.50
6. $VXRT – Vaxart, Inc. :
   1. Cash/sh = $8.50

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 06/18/2018 – 06/22/2018:

1) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.95
b. Sell at >~ $1.53

2) DFFN – Diffusion Pharmaceuticals Inc.
a. Buy at < ~ $0.44
b. Sell at >~ $0.69
c. Catalysts:
1. NA – Pilot Intervention to Empower HIV Clients as Prevention Advocates in Uganda; 20181031; 20190228; https://ClinicalTrials.gov/show/NCT03435497
2. NA – Multimodal MRI-guided rTMS to Treat Refractory Hallucinations; 20181101; 20181130; https://ClinicalTrials.gov/show/NCT01373866
3. NA – MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy; 20180901; 20180930; https://ClinicalTrials.gov/show/NCT02988921
4. NA – The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02965963
5. Phase 1 – Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection; 20190101; 20190131; https://ClinicalTrials.gov/show/NCT02647983
6. Phase 2 – The Iguratimod Effect on Lupus Nephritis (IGeLU); 20190101; 20190831; https://ClinicalTrials.gov/show/NCT02936375
7. Phase 1 – Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02507583
8. Phase 2 – Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas; 20181201; 20210630; https://ClinicalTrials.gov/show/NCT01966809
9. Phase 2 – MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS); 20171207; 20210521; https://ClinicalTrials.gov/show/NCT01643850
10. NA – Antibiotics and Activity Spaces: An Exploratory Study of Behaviour, Marginalisation, and Knowledge Diffusion; 20180430; 20181031; https://ClinicalTrials.gov/show/NCT03241316
11. Phase 3 – Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation; 20170801; 20180831; https://ClinicalTrials.gov/show/NCT01924065
12. NA – Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy; 20171201; 20180630; https://ClinicalTrials.gov/show/NCT00575432
13. NA – Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial; 20180731; 20181031; https://ClinicalTrials.gov/show/NCT03098732
14. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
15. Phase 2 – Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging; 20180501; 20181031; https://ClinicalTrials.gov/show/NCT01864317
16. NA – Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer; 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02178345
17. NA – ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE; 20190201; 20201031; https://ClinicalTrials.gov/show/NCT03296150
18. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
19. Phase 4 – The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals; 20201001; 20211031; https://ClinicalTrials.gov/show/NCT02536846
20. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
21. NA – Whole Body MRI With DWI for Monitoring Patients Treated for Testicular Cancer Stage II-III; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT03436901
22. NA – Development and Validation of Advanced MRI Methods for Clinical Applications; 20220626; 20221026; https://ClinicalTrials.gov/show/NCT03264300
23. Phase 2Phase 3 – Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency; 20240104; 20240104; https://ClinicalTrials.gov/show/NCT02004691
24. Early Phase 1 – Brain Dopaminergic Signaling in Opioid Use Disorders; 20201231; 20241231; https://ClinicalTrials.gov/show/NCT03190954
25. Phase 3 – Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects; 20210628; 20220623; https://ClinicalTrials.gov/show/NCT03393000
26. Phase 1 – Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas; 20190601; 20200731; https://ClinicalTrials.gov/show/NCT03054792
27. NA – Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis; 20191001; 20191031; https://ClinicalTrials.gov/show/NCT01974804
28. Phase 4 – Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02853045
29. NA – Pilot Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer; 20190601; 20190731; https://ClinicalTrials.gov/show/NCT01542879
30. NA – Impact of Epileptic Discharge on the Structural Connectivity of the Developing Brain; 20200101; 20200131; https://ClinicalTrials.gov/show/NCT03268824
31. NA – Healthy Lung Study- Development of 3 Tesla MRI Hardware and Software for Helium-3 Gas Imaging of the Lung: Healthy Volunteer Development Study; 20200331; 20200331; https://ClinicalTrials.gov/show/NCT03169673
32. Phase 1 – Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer; 20191001; 20191031; https://ClinicalTrials.gov/show/NCT03129776
33. NA – Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation; 20191101; 20201130; https://ClinicalTrials.gov/show/NCT02846272

3) PRSS – CafePress Inc. – Trading Below Cash
a. Buy at < ~ $1.26
b. Sell at >~ $1.99

4) RWLK – ReWalk Robotics Ltd.
a. Buy at < ~ $1.00
b. Sell at >~ $1.30

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 06/18/2018 – 06/22/2018, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 06/11/2018 – 06/15/2018:

1) UAVS – AgEagle Aerial Systems, Inc.
a. Buy at < ~ $1.61
b. Sell at >~ $10.95

2) HMNY – Helios and Matheson Analytics Inc. – Trading Below Cash
a. Buy at < ~ $0.33
b. Sell at >~ $2.00

3) DFFN – Diffusion Pharmaceuticals Inc.
a. Buy at < ~ $0.42
b. Sell at >~ $2.10
c. Catalysts:
1. NA – Pilot Intervention to Empower HIV Clients as Prevention Advocates in Uganda; 20181031; 20190228; https://ClinicalTrials.gov/show/NCT03435497
2. NA – Multimodal MRI-guided rTMS to Treat Refractory Hallucinations; 20181101; 20181130; https://ClinicalTrials.gov/show/NCT01373866
3. NA – MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy; 20180901; 20180930; https://ClinicalTrials.gov/show/NCT02988921
4. NA – The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02965963
5. Phase 1 – Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection; 20190101; 20190131; https://ClinicalTrials.gov/show/NCT02647983
6. Phase 2 – The Iguratimod Effect on Lupus Nephritis (IGeLU); 20190101; 20190831; https://ClinicalTrials.gov/show/NCT02936375
7. Phase 1 – Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02507583
8. Phase 2 – Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas; 20181201; 20210630; https://ClinicalTrials.gov/show/NCT01966809
9. Phase 2 – MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS); 20171207; 20210521; https://ClinicalTrials.gov/show/NCT01643850
10. NA – Antibiotics and Activity Spaces: An Exploratory Study of Behaviour, Marginalisation, and Knowledge Diffusion; 20180430; 20181031; https://ClinicalTrials.gov/show/NCT03241316
11. Phase 3 – Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation; 20170801; 20180831; https://ClinicalTrials.gov/show/NCT01924065
12. NA – Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy; 20171201; 20180630; https://ClinicalTrials.gov/show/NCT00575432
13. NA – Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial; 20180731; 20181031; https://ClinicalTrials.gov/show/NCT03098732
14. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
15. Phase 2 – Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging; 20180501; 20181031; https://ClinicalTrials.gov/show/NCT01864317
16. NA – Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer; 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02178345
17. NA – ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE; 20190201; 20201031; https://ClinicalTrials.gov/show/NCT03296150
18. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
19. Phase 4 – The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals; 20201001; 20211031; https://ClinicalTrials.gov/show/NCT02536846
20. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
21. NA – Whole Body MRI With DWI for Monitoring Patients Treated for Testicular Cancer Stage II-III; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT03436901
22. NA – Development and Validation of Advanced MRI Methods for Clinical Applications; 20220626; 20221026; https://ClinicalTrials.gov/show/NCT03264300
23. Phase 2Phase 3 – Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency; 20240104; 20240104; https://ClinicalTrials.gov/show/NCT02004691
24. Early Phase 1 – Brain Dopaminergic Signaling in Opioid Use Disorders; 20201231; 20241231; https://ClinicalTrials.gov/show/NCT03190954
25. Phase 3 – Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects; 20210628; 20220623; https://ClinicalTrials.gov/show/NCT03393000
26. Phase 1 – Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas; 20190601; 20200731; https://ClinicalTrials.gov/show/NCT03054792
27. Phase 1 – Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer; 20191001; 20191031; https://ClinicalTrials.gov/show/NCT03129776
28. Phase 4 – Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02853045
29. NA – Pilot Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer; 20190601; 20190731; https://ClinicalTrials.gov/show/NCT01542879
30. NA – Impact of Epileptic Discharge on the Structural Connectivity of the Developing Brain; 20200101; 20200131; https://ClinicalTrials.gov/show/NCT03268824
31. NA – Healthy Lung Study- Development of 3 Tesla MRI Hardware and Software for Helium-3 Gas Imaging of the Lung: Healthy Volunteer Development Study; 20200331; 20200331; https://ClinicalTrials.gov/show/NCT03169673
32. NA – Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis; 20191001; 20191031; https://ClinicalTrials.gov/show/NCT01974804
33. NA – Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation; 20191101; 20201130; https://ClinicalTrials.gov/show/NCT02846272

4) RXII – RXi Pharmaceuticals Corporation
a. Buy at < ~ $1.90
b. Sell at >~ $6.30
c. Catalysts:
1. Phase 2 enrollment completed – noted September 6, 2017. Full readouts due 1Q/2Q 2018. – Samcyprone – RXI-SCP-1502 – Cutaneous warts – Phase 2; 20180630; 20180630; http://investors.rxipharma.com/static-files/d04bbf93-5879-49fb-a0da-ae4d2d158ebd

5) CANF – Can-Fite BioPharma Ltd.
a. Buy at < ~ $1.24
b. Sell at >~ $2.70
c. Catalysts:
1. Phase 2 – Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC); 20180701; 20180930; https://ClinicalTrials.gov/show/NCT02128958
2. Phase 2 – A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02927314
3. Phase 2 – A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee; 20181201; 20190131; https://ClinicalTrials.gov/show/NCT00837291

6) SUNW – Sunworks, Inc.
a. Buy at < ~ $0.90
b. Sell at >~ $1.45

7) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.95
b. Sell at >~ $1.53

8) PRSS – CafePress Inc. – Trading Below Cash
a. Buy at < ~ $1.26
b. Sell at >~ $1.99

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 06/11/2018 – 06/15/2018, and Why?

[Michael DeVries]

“The Psychology of Money” => http://www.collaborativefund.com/blog/the-psychology-of-money/

What do you all think about all of that?

Let’s talk about it all herein, ok?

I hope this helps! Good Luck! and Have a Great Trading Week!

– Michael S. DeVries

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 06/04/2018 – 06/08/2018:

1) ONTX – Onconova Therapeutics, Inc.
a. Buy at < ~ $0.33
b. Sell at >~ $2.80
c. Catalysts:
1. Phase 1 – Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors; 20180501; 20181231; https://ClinicalTrials.gov/show/NCT02168725
2. Phase 1 – Three Dosing Schedules of Oral Rigosertib in MDS Patients; 20180401; 20181031; https://ClinicalTrials.gov/show/NCT02075034
3. Phase 3 – Controlled Study of Rigosertib Versus Physicians Choice of Treatment in MDS Patients After Failure of an HMA; 20180601; 20180930; https://ClinicalTrials.gov/show/NCT02562443
4. Phase 2 – Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia; 20220801; 20220831; https://ClinicalTrials.gov/show/NCT02730884
5. Phase 1Phase 2 – Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine; 20180601; 20181031; https://ClinicalTrials.gov/show/NCT01926587

2) UAVS – AgEagle Aerial Systems, Inc.
a. Buy at < ~ $1.61
b. Sell at >~ $10.95

3) IZEA – IZEA, Inc.
a. Buy at < ~ $1.37
b. Sell at >~ $7.60

4) DFFN – Diffusion Pharmaceuticals Inc.
a. Buy at < ~ $0.42
b. Sell at >~ $2.10
c. Catalysts:
1. NA – Pilot Intervention to Empower HIV Clients as Prevention Advocates in Uganda; 20181031; 20190228; https://ClinicalTrials.gov/show/NCT03435497
2. NA – Multimodal MRI-guided rTMS to Treat Refractory Hallucinations; 20181101; 20181130; https://ClinicalTrials.gov/show/NCT01373866
3. NA – MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy; 20180901; 20180930; https://ClinicalTrials.gov/show/NCT02988921
4. NA – The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02965963
5. Phase 1 – Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection; 20190101; 20190131; https://ClinicalTrials.gov/show/NCT02647983
6. Phase 2 – The Iguratimod Effect on Lupus Nephritis (IGeLU); 20190101; 20190831; https://ClinicalTrials.gov/show/NCT02936375
7. Phase 1 – Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02507583
8. Phase 2 – Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas; 20181201; 20210630; https://ClinicalTrials.gov/show/NCT01966809
9. Phase 2 – MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS); 20171207; 20210521; https://ClinicalTrials.gov/show/NCT01643850
10. NA – Antibiotics and Activity Spaces: An Exploratory Study of Behaviour, Marginalisation, and Knowledge Diffusion; 20180430; 20181031; https://ClinicalTrials.gov/show/NCT03241316
11. Phase 3 – Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation; 20170801; 20180831; https://ClinicalTrials.gov/show/NCT01924065
12. NA – Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy; 20171201; 20180630; https://ClinicalTrials.gov/show/NCT00575432
13. NA – Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial; 20180731; 20181031; https://ClinicalTrials.gov/show/NCT03098732
14. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
15. Phase 2 – Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging; 20180501; 20181031; https://ClinicalTrials.gov/show/NCT01864317
16. NA – Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer; 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02178345
17. NA – ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE; 20190201; 20201031; https://ClinicalTrials.gov/show/NCT03296150
18. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
19. Phase 4 – The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals; 20201001; 20211031; https://ClinicalTrials.gov/show/NCT02536846
20. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
21. NA – Whole Body MRI With DWI for Monitoring Patients Treated for Testicular Cancer Stage II-III; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT03436901
22. NA – Development and Validation of Advanced MRI Methods for Clinical Applications; 20220626; 20221026; https://ClinicalTrials.gov/show/NCT03264300
23. Phase 2Phase 3 – Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency; 20240104; 20240104; https://ClinicalTrials.gov/show/NCT02004691
24. Early Phase 1 – Brain Dopaminergic Signaling in Opioid Use Disorders; 20201231; 20241231; https://ClinicalTrials.gov/show/NCT03190954
25. Phase 3 – Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects; 20210628; 20220623; https://ClinicalTrials.gov/show/NCT03393000
26. Phase 1 – Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas; 20190601; 20200731; https://ClinicalTrials.gov/show/NCT03054792
27. Phase 1 – Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer; 20191001; 20191031; https://ClinicalTrials.gov/show/NCT03129776
28. Phase 4 – Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02853045
29. NA – Pilot Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer; 20190601; 20190731; https://ClinicalTrials.gov/show/NCT01542879
30. NA – Impact of Epileptic Discharge on the Structural Connectivity of the Developing Brain; 20200101; 20200131; https://ClinicalTrials.gov/show/NCT03268824
31. NA – Healthy Lung Study- Development of 3 Tesla MRI Hardware and Software for Helium-3 Gas Imaging of the Lung: Healthy Volunteer Development Study; 20200331; 20200331; https://ClinicalTrials.gov/show/NCT03169673
32. NA – Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis; 20191001; 20191031; https://ClinicalTrials.gov/show/NCT01974804
33. NA – Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation; 20191101; 20201130; https://ClinicalTrials.gov/show/NCT02846272

5) RXII – RXi Pharmaceuticals Corporation
a. Buy at < ~ $1.90
b. Sell at >~ $6.30
c. Catalysts:
1. Phase 2 enrollment completed – noted September 6, 2017. Full readouts due 1Q/2Q 2018. – Samcyprone – RXI-SCP-1502 – Cutaneous warts – Phase 2; 20180630; 20180630; http://investors.rxipharma.com/static-files/d04bbf93-5879-49fb-a0da-ae4d2d158ebd

6) ALT – Altimmune, Inc.
a. Buy at < ~ $0.41
b. Sell at >~ $1.34
c. Catalysts:
1. Phase 1 – Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B; 20171013; 20180629; https://ClinicalTrials.gov/show/NCT02496897
2. Phase 2 – Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX; 20180307; 20180731; https://ClinicalTrials.gov/show/NCT03232567
3. Phase 1 – NasoShield Study of Safety and Immunogenicity; 20180601; 20190831; https://ClinicalTrials.gov/show/NCT03352466

7) SUNW – Sunworks, Inc.
a. Buy at < ~ $0.90
b. Sell at >~ $1.45

8) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.95
b. Sell at >~ $1.53

9) PRSS – CafePress Inc. – Trading Below Cash
a. Buy at < ~ $1.26
b. Sell at >~ $1.99

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 06/04/2018 - 06/08/2018, and Why?

[Michael DeVries]

Meet AVA, Autodesk’s New Virtual Assistant => https://finance.yahoo.com/video/meet-ava-autodesks-virtual-assistant-205034230.html

What do you think of Autodesk’s New Virtual Assistant, AVA?

What other company’s have good Virtual Assistants / Chatbots?

Let’s discuss, compare and contrast them all herein, ok?

I hope this all helps and Have a Great Day!

– Michael S. DeVries

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 05/29/2018 – 06/01/2018:

1) ONTX – Onconova Therapeutics, Inc.
a. Buy at < ~ $0.33
b. Sell at >~ $2.80
c. Catalysts:
1. Phase 3 – Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01928537
2. Phase 1 – Three Dosing Schedules of Oral Rigosertib in MDS Patients; 20180401; 20181031; https://ClinicalTrials.gov/show/NCT02075034
3. Phase 3 – Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01241500
4. Phase 2 – Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01904682
5. Phase 1Phase 2 – Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine; 20180601; 20181031; https://ClinicalTrials.gov/show/NCT01926587
6. Phase 2 – Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia; 20220801; 20220831; https://ClinicalTrials.gov/show/NCT02730884
7. Phase 1 – Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors; 20180501; 20181231; https://ClinicalTrials.gov/show/NCT02168725
8. Phase 3 – Controlled Study of Rigosertib Versus Physicians Choice of Treatment in MDS Patients After Failure of an HMA; 20180601; 20180930; https://ClinicalTrials.gov/show/NCT02562443

2) UAVS – AgEagle Aerial Systems, Inc.
a. Buy at < ~ $1.61
b. Sell at >~ $10.95

3) DFFN – Diffusion Pharmaceuticals Inc.
a. Buy at < ~ $0.42
b. Sell at >~ $2.10
c. Catalysts:
1. NA – Pilot Intervention to Empower HIV Clients as Prevention Advocates in Uganda; 20181031; 20190228; https://ClinicalTrials.gov/show/NCT03435497
2. NA – Multimodal MRI-guided rTMS to Treat Refractory Hallucinations; 20181101; 20181130; https://ClinicalTrials.gov/show/NCT01373866
3. NA – MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy; 20180901; 20180930; https://ClinicalTrials.gov/show/NCT02988921
4. NA – The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02965963
5. Phase 1 – Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection; 20190101; 20190131; https://ClinicalTrials.gov/show/NCT02647983
6. Phase 2 – The Iguratimod Effect on Lupus Nephritis (IGeLU); 20190101; 20190831; https://ClinicalTrials.gov/show/NCT02936375
7. Phase 1 – Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02507583
8. Phase 2 – Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas; 20181201; 20210630; https://ClinicalTrials.gov/show/NCT01966809
9. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
10. NA – Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy; 20171201; 20180630; https://ClinicalTrials.gov/show/NCT00575432
11. Phase 2 – MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS); 20171207; 20210521; https://ClinicalTrials.gov/show/NCT01643850
12. Phase 3 – Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation; 20170801; 20180831; https://ClinicalTrials.gov/show/NCT01924065
13. NA – Hepatic Fibrosis Assessment Using Multiparametric Magnetic Resonance Imaging; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT02480972
14. NA – Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer; 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02178345
15. NA – Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial; 20180731; 20181031; https://ClinicalTrials.gov/show/NCT03098732
16. NA – Antibiotics and Activity Spaces: An Exploratory Study of Behaviour, Marginalisation, and Knowledge Diffusion; 20180430; 20181031; https://ClinicalTrials.gov/show/NCT03241316
17. Phase 2 – Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging; 20180501; 20181031; https://ClinicalTrials.gov/show/NCT01864317
18. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
19. Phase 4 – The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals; 20201001; 20211031; https://ClinicalTrials.gov/show/NCT02536846
20. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
21. NA – Whole Body MRI With DWI for Monitoring Patients Treated for Testicular Cancer Stage II-III; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT03436901
22. NA – Development and Validation of Advanced MRI Methods for Clinical Applications; 20220626; 20221026; https://ClinicalTrials.gov/show/NCT03264300
23. Phase 2Phase 3 – Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency; 20240104; 20240104; https://ClinicalTrials.gov/show/NCT02004691
24. Early Phase 1 – Brain Dopaminergic Signaling in Opioid Use Disorders; 20201231; 20241231; https://ClinicalTrials.gov/show/NCT03190954
25. Phase 3 – Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects; 20210628; 20220623; https://ClinicalTrials.gov/show/NCT03393000
26. NA – Healthy Lung Study- Development of 3 Tesla MRI Hardware and Software for Helium-3 Gas Imaging of the Lung: Healthy Volunteer Development Study; 20200331; 20200331; https://ClinicalTrials.gov/show/NCT03169673
27. NA – Pilot Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer; 20190601; 20190731; https://ClinicalTrials.gov/show/NCT01542879
28. Phase 1 – Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas; 20190601; 20200731; https://ClinicalTrials.gov/show/NCT03054792
29. NA – ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE; 20190201; 20201031; https://ClinicalTrials.gov/show/NCT03296150
30. Phase 4 – Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02853045
31. NA – Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation; 20191101; 20201130; https://ClinicalTrials.gov/show/NCT02846272
32. NA – Impact of Epileptic Discharge on the Structural Connectivity of the Developing Brain; 20200101; 20200131; https://ClinicalTrials.gov/show/NCT03268824
33. Phase 1 – Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer; 20191001; 20191031; https://ClinicalTrials.gov/show/NCT03129776
34. NA – Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis; 20191001; 20191031; https://ClinicalTrials.gov/show/NCT01974804

4) RXII – RXi Pharmaceuticals Corporation
a. Buy at < ~ $1.90
b. Sell at >~ $6.30
c. Catalysts:
1. Phase 2 – Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts); 20180101; 20180531; https://ClinicalTrials.gov/show/NCT02640820
2. Phase 2 enrollment completed – noted September 6, 2017. Full readouts due 1Q/2Q 2018. – Samcyprone – RXI-SCP-1502 – Cutaneous warts – Phase 2; 20180630; 20180630; http://investors.rxipharma.com/static-files/d04bbf93-5879-49fb-a0da-ae4d2d158ebd

5) ALT – Altimmune, Inc.
a. Buy at < ~ $0.41
b. Sell at >~ $1.34
c. Catalysts:
1. Phase 1 – Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B; 20171013; 20180629; https://ClinicalTrials.gov/show/NCT02496897
2. Phase 2 – Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX; 20180307; 20180731; https://ClinicalTrials.gov/show/NCT03232567
3. Phase 1 – NasoShield Study of Safety and Immunogenicity; 20180601; 20190831; https://ClinicalTrials.gov/show/NCT03352466

6) SUNW – Sunworks, Inc.
a. Buy at < ~ $0.90
b. Sell at >~ $1.45

7) PRSS – CafePress Inc. – Trading Below Cash
a. Buy at < ~ $1.26
b. Sell at >~ $1.99

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 05/29/2018 - 06/01/2018, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 05/11/2018 include:

1. $CLDX – Celldex Therapeutics, Inc. :
   1. Book/sh = $1.73
2. $DCAR – DropCar, Inc. :
   1. Book/sh = $3.01
3. $JAGX – Jaguar Health, Inc. :
   1. Book/sh = $0.57
4. $KOOL – Cesca Therapeutics Inc. :
   1. Book/sh = $3.36
5. $NNDM – Nano Dimension Ltd. :
   1. Book/sh = $1.44
6. $OVAS – OvaScience, Inc. :
   1. Book/sh = $1.80
7. $SEED – Origin Agritech Limited :
   1. Book/sh = $0.76
8. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $3.16

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

#StockPicks #Stock #Market #Trading

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 05/11/2018 include:

1. $CLDX – Celldex Therapeutics, Inc. :
   1. Cash/sh = $1.00
2. $DCAR – DropCar, Inc. :
   1. Cash/sh = $1.92
3. $EGLT – Egalet Corporation :
   1. Cash/sh = $2.31
4. $FCSC – Fibrocell Science, Inc. :
   1. Cash/sh = $0.77
5. $OPHT – Ophthotech Corporation :
   1. Cash/sh = $4.63
6. $OVAS – OvaScience, Inc. :
   1. Cash/sh = $1.88
7. $RTTR – Ritter Pharmaceuticals, Inc. :
   1. Cash/sh = $4.50
8. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Cash/sh = $3.20
9. $VVUS – VIVUS, Inc. :
   1. Cash/sh = $2.14
10. $VXRT – Vaxart, Inc. :
    1. Cash/sh = $8.50

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 05/14/2018 – 05/18/2018:

1) UAVS – AgEagle Aerial Systems, Inc.
a. Buy at < ~ $1.70
b. Sell at >~ $10.95

2) RXII – RXi Pharmaceuticals Corporation
a. Buy at < ~ $1.90
b. Sell at >~ $6.30
c. Catalysts:
1. Phase 2 completion of enrollment announced June 21, 2017. Data to be presented May 17, 2018. – RXI-109-1501 – Dermal scarring – Phase 2; 20180517; 20180517; http://investors.rxipharma.com/news-releases/news-release-details/rxi-pharmaceuticals-present-update-its-clinical-and-cosmetic
2. Phase 2 – Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts); 20180101; 20180531; https://ClinicalTrials.gov/show/NCT02640820
3. Phase 2 enrollment completed – noted September 6, 2017. Full readouts due 1Q/2Q 2018. – Samcyprone – RXI-SCP-1502 – Cutaneous warts – Phase 2; 20180630; 20180630; http://investors.rxipharma.com/static-files/d04bbf93-5879-49fb-a0da-ae4d2d158ebd
4. Phase 2 enrollment completed – noted September 6, 2017. Data to be presented May 18, 2018. – Samcyprone – RXI-SCP-1502 – Cutaneous warts – Phase 2; 20180518; 20180518; http://investors.rxipharma.com/news-releases/news-release-details/rxi-pharmaceuticals-present-update-its-clinical-and-cosmetic

3) CRIS – Curis, Inc.
a. Buy at < ~ $0.47
b. Sell at >~ $1.00
c. Catalysts:
1. Phase 1 – A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas; 20190101; 20200131; https://ClinicalTrials.gov/show/NCT02812875
2. Phase 1 update from CUDC-907, CA-170 and potential additional programs; 2016; ; https://finance.yahoo.com/news/curis-present-bio-ceo-investor-210500148.html
3. Phase 1 – A Study of CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT03328078
4. Phase 1 – Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma; 20191001; 20221031; https://ClinicalTrials.gov/show/NCT02909777

4) SUNW – Sunworks, Inc.
a. Buy at < ~ $0.90
b. Sell at >~ $1.45

5) PRSS – CafePress Inc. – Trading Below Cash
a. Buy at < ~ $1.26
b. Sell at >~ $1.99

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 05/14/2018 – 05/18/2018, and Why?

[Michael DeVries]

Check out “Google Duplex: An AI System for Accomplishing Real-World Tasks Over the Phone” => https://ai.googleblog.com/2018/05/duplex-ai-system-for-natural-conversation.html

What do you all think about Google Duplex?

What other new Use Cases do you foresee for which something like Google Duplex would be able to automate?

What do you all think will be the next step / development in Conversational Interfaces beyond Google Dupliex?

Let’s discuss all of this herein, ok?

I hope this all helps and Have a Great Day!

– Michael S. DeVries

[Author]

Posts